Targeted Therapy in Ovarian Cancer

Table 4

Review of multikinase inhibitors that have been studied in ovarian cancer. RR: response rate, SD: stable disease, HTN: hypertension, HFS: hand-foot syndrome.

Agent(s)	Authors	RR	SD	Toxicities
Sorafenib	Matei et al.	2/59 partial	20/59	Rash, GI, cardiovascular, metabolic, pulmonary
Sorafenib + bevacizumab	Azad et al.	6/13 partial		HTN, diarrhea, HFS, thrombocytopenia, proteinuria, fistula
Sorafenib + gemcitabine	Welch et al.	6/18 partial	10/18	Lymphopenia, thrombocytopenia, HTN, HFS, pain, neutropenia, hypokalemia
Imatinib	Coleman et al.	0/12	4/12	Fatigue, nausea/vomiting, rash, neutropenia
Imatinib	Alberts et al.	0/19		Hematologic, metabolic
Imatinib	Schilder et al.	1/56 complete		Neutropenia, GI, dermatologic, pain, electrolyte disturbances